Opatanol (Olopatadine)

Olopatadine works by selectively blocking histamine H1 receptors on the ocular surface and stabilizing mast cells. This dual action prevents the release of histamine and other inflammatory mediators, thereby reducing the allergic response that causes eye irritation.

The appropriate dose is determined by the prescribing clinician. Typically, one drop is instilled into each affected eye once or twice daily, or as directed by the healthcare professional based on the severity of symptoms.

Safety data in pregnancy and lactation are limited. Opatanol should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Olopatadine offers both H1‑receptor antagonism and mast‑cell‑stabilizing activity, delivering rapid symptom relief and longer‑lasting control compared with agents that act solely as antihistamines. This combined mechanism often results in better overall efficacy for allergic eye conditions.

Store Opatanol at room temperature, below 25 °C. Keep the bottle in its original packaging, protect it from moisture and direct light, and ensure the cap is tightly closed when not in use.

Wash your hands, tilt the head back slightly, and pull down the lower eyelid to create a small pocket. Instill the prescribed number of drops into the conjunctival sac, avoid touching the tip to the eye, and close the eye gently for a few seconds.

Rare but serious adverse reactions include severe eye irritation, corneal ulceration, significant vision changes, and systemic allergic responses such as anaphylaxis. If any of these occur, seek immediate medical attention.

Individuals with known hypersensitivity to olopatadine or any of the formulation’s excipients should avoid Opatanol. Patients who have experienced severe ocular reactions to similar antihistamine eye drops should also consult a healthcare professional before use.